Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Cancer Biology and Therapy is Scopus-indexed (Q1, CiteScore 8.4), WoS SCIE, DOAJ. Published by Taylor and Francis Ltd..
Checked against the index lists dated .
ISSN 1538-4047Verify ISSN ↗1555-8576Verify ISSN ↗
Publisher: Taylor and Francis Ltd.
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Oncology | 72 / 428 | 83rd | Q1 |
| Pharmacology | 56 / 328 | 83rd | Q1 |
| Cancer Research | 61 / 233 | 74th | Q2 |
| Molecular Medicine | 48 / 179 | 73rd | Q2 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2002–present, best quartile Q1, CiteScore 8.4.
Cancer Biology and Therapy is Q1 in Oncology (rank 72 of 428), Q1 in Pharmacology (rank 56 of 328) and Q2 in Cancer Research (rank 61 of 233), by CiteScore 2025. It is ranked in 4 subject areas in all.
Cancer Biology and Therapy is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 8.4, which places it in quartile Q1 at the 83rd percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 1.407, quartile Q1, with an H-index of 138.
The publisher lists an article processing charge of about US$2,970 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Cancer Biology and Therapy is published by Taylor and Francis Ltd. Its print ISSN is 1538-4047 and its online ISSN is 1555-8576.
Yes — indexed in the Science Citation Index Expanded.
Yes — it is an open-access journal, listed in DOAJ.
Cancer Biology and Therapy has an h-index of 154 and a 2-year mean of 6.79 citations per paper (OpenAlex). Its Scopus CiteScore is 8.4, quartile Q1. On 2-year citations it ranks #28 of 424 Scopus journals in Oncology.
Cancer Biology and Therapy published 88 papers in 2025; its busiest recent year was 2018 with 192. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 99 research articles (2025–2026), authors are most often from China (65.7%), United States (12.6%) and Canada (3.5%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 26 retracted papers are recorded (5 per 1,000 papers). The Problematic Paper Screener flags 1 of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.